Labcorp and BML announce expansion of clinical laboratory testing capabilities in Japan

Advanced technology supports drug development across diseases including cancer and cerebrovascular disease

Labcorp and Providence expand strategic laboratory relationship

Patients and Providers in Oregon Region Will Gain Broader Access to Labcorp's Diagnostic Testing and Laboratory Services Labcorp and Providence Health & Services – Oregon (Providence Oregon) have entered into an agreement for Labcorp to acquire select assets of Providence Oregon's outreach

Algorithmic prediction of response to checkpoint inhibitors

Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient

The inflamed phenotype in PD-L1 negative melanoma and response to checkpoint inhibitors

An algorithmic approach to cancer immune profiling

Validation of a custom RNA-Seq approach to cancer immune profiling

The inflamed phenotype in PD-L1 negative NSCLC and response to checkpoint inhibitors

Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification

NGS reveals specimen characteristics have minimal impact on immune gene expression signature